Back to the main directory
EarningsReview / Equity
- INVEST SECURITIES - BIGBEN : Une AK de Nacon qui ne résout pas grand-chose - ACHAT, OC 5,5€ vs 5,8€ by Invest Securities
- Non material data changes by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Hiwin (2049 TT) by HSBC
- Non-material data changes by BNP Paribas Exane
- BlueNord (Buy, TP: NOK610.00) - Focusing on Tyra by DnB Markets
- Industrivärden (Hold, TP: SEK380.00) - Much to like, but fairly valued by DnB Markets
- Sweco Minor model adjustments by DnB Markets
- Moonpig (MOON LN) by HSBC
- What to expect from H2’24? by BNP Paribas Exane
- 2Q24 preview: derisked by BNP Paribas Exane
- Playing defense by BNP Paribas Exane
- PFAS: one growth driver among many by BNP Paribas Exane
- Wallenstam - Sell/SEK 45 (44): Buybacks will not move the needle by Nordea
- Addressing investors’ key concerns by BNP Paribas Exane
- Summertime weakness by BNP Paribas Exane
- Potential for PFAS removal to contribute to customer adoption by BNP Paribas Exane
- The gap is getting wider by BNP Paribas Exane
- INVEST SECURITIES - CARMAT : Nouvelle rallonge financière, S1 encourageant - ACHAT, OC 7,6€ vs 10,0€ by Invest Securities
- Non material data changes by BNP Paribas Exane
- Volue - A fair bid on a standalone basis by Danske Bank Equity Research
- Expect a muted 1Q; tariff hikes to lift growth from 2Q by BNP Paribas Exane
- Something old, something new… (re)initiate at Outperform by BNP Paribas Exane
- Oryzon Genomics - Strengthening vafidemstat’s IP profile by Edison Investment Research